Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00064792 · ClinicalTrials.gov registry record · Phase 2
Simvastatin Therapy in Smith-Lemli-Opitz Syndrome
A Phase 2 study of Smith-Lemli-Opitz Syndrome, sponsored by Forbes Porter, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT00064792 is a Phase 2 study of Smith-Lemli-Opitz Syndrome that has completed, run by Forbes Porter, M.D.. The registered enrollment target is 23 participants, below the 620-participant average among 4 other Smith-Lemli-Opitz Syndrome trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00064792, a Phase 2 study of Smith-Lemli-Opitz Syndrome, has completed, sponsored by Forbes Porter, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the safety and effectiveness of simvastatin in treating children with Smith-Lemli-Opitz syndrome (SLOS). Patients with this inherited disease are deficient in an enzyme that converts a substance called 7-dehydrocholesterol (7-DHC) to cholesterol. Cholesterol synthesis is impaired, causing birth defects and mental retardation. This study will examine whether simvastatin can increase the amount of the deficient enzyme, thereby lowering 7-DHC and increasing cholesterol. It will examine the safety of simvastatin in affected children and its effects on their behavioral problems. Children between 4 and 18 years of age with mild to typical SLOS may be eligible for this study. Participants will be evaluated at the NIH Clinical Center in Bethesda, MD, and at the Kennedy Krieger Institute in Baltimore, MD, upon admission to the study and again at 6, 12, 20, and 26 months. The visits will last 3 to 4 days, and will include a medical history and physical examination, photographs to document medical findings, and other procedures detailed below. In addition, blood samples will be collected at 1, 3, 9, 14, 15, 17, and 23 months. Parents will complete several questionnaires during the study. Procedures include the following: * Simvastatin and cholesterol supplementation therapy. Patients take cholesterol supplements (50 milligrams per kilogram per day) plus simvastatin (0.5 mg/kg/day for 6 weeks and then 1 mg/kg/day) for 12 months, and cholesterol supplements plus a placebo for 12 months. * Blood draws to check liver, muscle, and kidney function, hormone levels, vitamin D levels, blood counts, cholesterol and 7-DHC levels, and lipoprotein levels. Some extra blood is drawn for research purposes. * Urine collection. Urine is collected using a toilet hat. For children who are not toilet trained, urine is collected in a bag taped to the skin with an adhesive. * Electroretinogram (ERG) to measure the function of the retina, the light-sensitive tissue at the b
Conditions Studied
Interventions
- DRUG Simvastatin Susp.
- DRUG OraPlus
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2003-07 |
| Est. Completion | 2010-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00064792
The ClinicalTrials.gov registry entry for NCT00064792 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 620-participant average among 4 other Smith-Lemli-Opitz Syndrome trials with a reported enrollment target (96% lower). The listed sponsor is Forbes Porter, M.D., which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Smith-Lemli-Opitz Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Simvastatin Susp. is the first listed.
NCT00064792 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT00064792 about?
NCT00064792 is a clinical study titled "Simvastatin Therapy in Smith-Lemli-Opitz Syndrome". This study will evaluate the safety and effectiveness of simvastatin in treating children with Smith-Lemli-Opitz syndrome (SLOS). Patients with this inherited disease are deficient in an enzyme that converts a substance called 7-dehydrocholesterol (7-DHC) to cholesterol. Cholesterol synthesis is imp...
What is the current status of trial NCT00064792?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2003-07. Estimated completion is 2010-12.
What conditions does trial NCT00064792 study?
This clinical trial studies the following conditions: Smith-Lemli-Opitz Syndrome.
What interventions are being tested in trial NCT00064792?
The interventions under investigation include: Simvastatin Susp. (DRUG), OraPlus (DRUG).
Who is sponsoring clinical trial NCT00064792?
This trial is sponsored by Forbes Porter, M.D., which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00064792 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smith-Lemli-Opitz Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
RECRUITING · Phase 2
-
Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism
RECRUITING
-
Estimation of the Carrier Frequency and Incidence of Smith-Lemli-Opitz Syndrome in African Americans
COMPLETED
-
Study of Smith-Lemli-Opitz Syndrome
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.